Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
Oncologist 2020 Nov 20;[EPub Ahead of Print], LA Sena, J Fountain, P Isaacsson Velho, SJ Lim, H Wang, E Nizialek, N Rathi, R Nussenzveig, BL Maughan, MG Velez, R Ashkar, AC Larson, CC Pritchard, N Adra, AH Bryce, N Agarwal, DM Pardoll, JR Eshleman, TL Lotan, ES AntonarakisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.